Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer

Experimental Cell Research

Volumn 322, Issue 1, 2014, Pages 168-177

  Ochi, Nobuaki ^a,b   Takigawa, Nagio ^b   Harada, Daijiro ^a   Yasugi, Masayuki ^a   Ichihara, Eiki ^a   Hotta, Katsuyuki ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^c  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

EGFR; ERK; Gefitinib; Lung cancer; Resistance; Src

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CELL STRUCTURE; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME REACTIVATION; FEMALE; GROWTH INHIBITION; IC 50; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR VOLUME; UPREGULATION;

EGFR; ERK; GEFITINIB; LUNG CANCER; RESISTANCE; SRC;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG NEOPLASMS; NITROSAMINES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUINAZOLINES;

EID: 84893717465     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.01.007     Document Type: Article

References (60)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
2. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Nat. Acad. Sci. U.S.A 2004, 101:13306-13311.
4. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 2006, 12:3908-3914.
5. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 2006, 12:839-844.
6. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
7. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
8. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Nat. Acad. Sci. U.S.A 2005, 102:7665-7670.
9. Riely G.J. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J. Thorac. Oncol. 2008, 3:S146-S149.
10. Kobayashi S., Ji H., Yuza Y., Meyerson M., Wong K.-K., Tenen D.G., et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005, 65:7096-7101.
11. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
12. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 118:2609-2619.
13. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2:e17.
14. Koch A., Fohlin H., Sörenson S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J. Thorac. Oncol. 2009, 4:326-332.
15. Parsons A., Daley A., Begh R., Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. Br. Med. J. 2010, 340:b5569.
16. Kawaguchi T., Matsumura A., Fukai S., Tamura A., Saito R., Zell J.A., et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J. Thorac. Oncol. 2010, 5:1001-1010.
17. Kawaguchi T., Takada M., Kubo A., Matsumura A., Fukai S., Tamura A., et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J. Thorac. Oncol. 2010, 5:620-630.
18. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353:123-132.
19. Hotta K., Kiura K., Takigawa N., Fujiwara Y., Tabata M., Ueoka H., et al. Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Lung Cancer 2008, 62:236-241.
20. Reck M., van Zandwijk N., Gridelli C., Baliko Z., Rischin D., Allan S., et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J. Thorac. Oncol. 2010, 5:1616-1622.
21. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 2004, 3:465-472.
22. Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T., et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 2007, 67:7807-7814.
23. Koizumi F., Shimoyama T., Taguchi F., Saijo N., Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int. J. Cancer 2005, 116:36-44.
24. Kelley D.J., Mestre J.R., Subbaramaiah K., Sacks P.G., Schantz S.P., Tanabe T., et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997, 18:795-799.
25. Huang R.-Y., Li M.-Y., Hsin M.K.Y., Underwood M.J., Ma L.T., Mok T.S.K., et al. 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene 2011, 30:106-116.
26. Schuller H.M., Cekanova M. NNK-induced hamster lung adenocarcinomas over-express beta2-adrenergic and EGFR signaling pathways. Lung Cancer 2005, 49:35-45.
27. DOLL R., HILL A.B. The mortality of doctors in relation to their smoking habits; a preliminary report. Br. Med. J. 1954, 1:1451-1455.
28. Gealy R., Zhang L., Siegfried J.M., Luketich J.D., Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women,. Cancer Epidemiol. Biomark. Prev. 1999, 8:297-302.
29. Massion P.P., Carbone D.P. The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respir. Res. 2003, 4:12.
30. Lubin J.H., Alavanja M.C.R., Caporaso N., Brown L.M., Brownson R.C., Field R.W., et al. Cigarette smoking and cancer risk: modeling total exposure and intensity. Am. J. Epidemiol. 2007, 166:479-489.
31. Zhou W., Heist R.S., Liu G., Park S., Neuberg D.S., Asomaning K., et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer 2006, 53:375-380.
32. Li C.-T., Marek M., Guclu S.Z., Kim Y., Meshref M., Qin S., et al. Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. J. Cancer 2011, 2:52-61.
33. Kaneda H., Tamura K., Kurata T., Uejima H., Nakagawa K., Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 2004, 46:247-254.
34. Yang C.-H., Shih J.-Y., Chen K.-C., Yu C.-J., Yang T.-Y., Lin C.-P., et al. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 2006, 107:1873-1882.
35. Jida M., Toyooka S., Mitsudomi T., Takano T., Matsuo K., Hotta K., et al. Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. Cancer Sci. 2009, 100:1931-1934.
36. Hoffmann D., Hoffmann I., El-Bayoumy K. The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem. Res. Toxicol. 2001, 14:767-790.
37. Slebos R.J., Hruban R.H., Dalesio O., Mooi W.J., Offerhaus G.J., Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J. Nat. Cancer Inst. 1991, 83:1024-1027.
38. Westra W.H., Slebos R.J., Offerhaus G.J., Goodman S.N., Evers S.G., Kensler T.W., et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993, 72:432-438.
39. Ahrendt S.A., Decker P.A., Alawi E.A., Zhu Yr Y.R., Sanchez-Cespedes M., Yang S.C., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001, 92:1525-1530.
40. Porta M., Crous-Bou M., Wark P.A., Vineis P., Real F.X., Malats N., et al. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat. Res. 2009, 682:83-93.
41. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer,. Clin. Cancer Res. 2007, 13:2890-2896.
42. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9:962-972.
43. Gonzalez-Suarez E., Jacob A.P., Jones J., Miller R., Roudier-Meyer M.P., Erwert R., et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
44. Z.-N. Tang, F. Zhang, P. Tang, X.-W. Qi, J. Jiang, RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation, Oncol. Rep. (2011).
45. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
46. Irby R.B., Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 2000, 19:5636-5642.
47. Masaki T., Igarashi K., Tokuda M., Yukimasa S., Han F., Jin Y.J., et al. pp60c-src activation in lung adenocarcinoma. Eur. J. Cancer 2003, 39:1447-1455.
48. Johnson F.M., Saigal B., Talpaz M., Donato N.J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells,. Clin. Cancer Res. 2005, 11:6924-6932.
49. Song L., Morris M., Bagui T., Lee F.Y., Jove R., Haura E.B. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006, 66:5542-5548.
50. Maa M.C., Leu T.H., McCarley D.J., Schatzman R.C., Parsons S.J. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Nat. Acad. Sci. U.S.A 1995, 92:6981-6985.
51. Biscardi J.S., Ishizawar R.C., Silva C.M., Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000, 2:203-210.
52. Sos M.L., Michel K., Zander T., Weiss J., Frommolt P., Peifer M., et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 2009, 119:1727-1740.
53. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
54. Tsao M.-S., Sakurada A., Cutz J.-C., Zhu C.-Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353:133-144.
55. Zhang J., Kalyankrishna S., Wislez M., Thilaganathan N., Saigal B., Wei W., et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am. J. Pathol. 2007, 170:366-376.
56. Koppikar P., Choi S.-H., Egloff A.M., Cai Q., Suzuki S., Freilino M., et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin. Cancer Res. 2008, 14:4284-4291.
57. Fu Y.-N., Yeh C.-L., Cheng H.H.-Y., Yang C.-H., Tsai S.-F., Huang S.-F., et al. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene 2008, 27:957-965.
58. Haura E.B., Tanvetyanon T., Chiappori A., Williams C., Simon G., Antonia S., et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1387-1394.
59. Ercan D., Xu C., Yanagita M., Monast C.S., Pratilas C.A., Montero J., et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012, 2:934-947.
60. Filosto S., Baston D.S., Chung S., Becker C.R., Goldkorn T. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells. Mol. Cancer Ther. 2013, 12:1579-1590.